ClinicalTrials.gg
CompletedNCT06687759Updated Apr 13, 2026

A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

A Phase 1 interventional study of [14C]Calderasib in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Jun 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to learn what happens to calderasib in a healthy person's body over time and how it is cleared from the body.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Key inclusion criteria include but are not limited to the following:

  • Is in good health based on medical history, physical examination,vital signs measurements, and (ECG)s performed before randomization.
  • Has a (BMI) 18 to 32 kg/m2, inclusive, at screening

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Has a history of cancer.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Carbon-14 radiolabeled [14C] MK-1084

    Participants receive single oral dose of calderasib on Day 1.

    Drug: [14C]Calderasib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of plasma Calderasib

    Bood samples will be collected to determine the AUC0-inf of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  2. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of plasma Calderasib

    Blood samples will be collected to determine the AUC0-last of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  3. Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of plasma Calderasib

    Blood samples will be collected to determine the AUC0-24 of plasma calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  4. Maximum Concentration (Cmax) of plasma Calderasib

    Blood samples will be collected to determine the Cmax of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  5. Concentration at 24 hours postdose (C24) of plasma Calderasib

    Blood samples will be collected to determine the C24 of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  6. Time to Reach Maximum Concentration (Tmax) of plasma Calderasib

    Blood samples will be collected to determine the Tmax of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  7. Apparent Half Life (t½) of plasma Calderasib

    Blood samples will be collected to determine the t1/2 of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  8. Apparent Total Clearance (CL/F) of plasma Calderasib

    Blood samples will be collected to determine the CL/F of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  9. Apparent Volume of Distribution during the Terminal Elimination Phase (Vz/F) of plasma Calderasib

    Blood samples will be collected to determine the Vz/F of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  10. AUC0-inf/Total Radioactivity Ratio of plasma Calderasib

    Blood samples will be collected to determine the AUC0-inf/Total Radioactivity Ratio of calderasib in plasma.

    Time frame: Predose and at designated timepoints up to Day 15

  11. Amount Excreted in the Urine (Aeu) of Calderasib

    Urine samples will be collected to determine the Aeu of calderasib

    Time frame: Predose and at designated timepoints up to Day 15

  12. Cumulative Aeu of Calderasib

    Urine samples will be collected to determine the cumulative Ae of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  13. Percentage Excreted in the Urine (feu) of Calderasib

    Urine samples will be collected to determine the feu of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  14. Cumulative feu of Calderasib

    Urine samples will be collected to determine the cumulative feu of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  15. Amount Excreted in the Feces (Aef) of Calderasib

    Feces samples will be collected to determine the Aef of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  16. Cumulative Aef of Calderasib

    Feces samples will be collected to determine the cumulative Aef of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  17. Percentage Excreted in the Feces (fef) of Calderasib

    Feces samples will be collected to determine the fef of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  18. Cumulative fef of Calderasib

    Feces samples will be collected to determine the cumulative fef of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  19. Metabolites in Plasma of Calderasib

    Blood samples will be collected to determine the metabolites of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  20. Metabolites in Urine of Calderasib

    Urine samples will be collected to determine the metabolites of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

  21. Metabolites in Feces of Calderasib

    Feces samples will be collected to determine the metabolites of calderasib.

    Time frame: Predose and at designated timepoints up to Day 15

Secondary outcomes

  1. Number of Participants Experiencing an Adverse Event (AE)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.

    Time frame: Up to ~ 28 days

  2. Number of Participants Discontinuing Study Treatment due to an AE

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.

    Time frame: Up to ~ 28 days

07

Study locations

1 site
  • Fortea CRU Madison (Site 0001)
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Aug 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Jun 26, 2024
Primary completionActual
Aug 7, 2024
CompletionActual
Aug 7, 2024
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06687759
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Jun 26, 2024
Primary completion
Aug 7, 2024
Completion
Aug 7, 2024
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calderasib

Start the discussion